TWI380829B - 具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法 - Google Patents

具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法 Download PDF

Info

Publication number
TWI380829B
TWI380829B TW094138786A TW94138786A TWI380829B TW I380829 B TWI380829 B TW I380829B TW 094138786 A TW094138786 A TW 094138786A TW 94138786 A TW94138786 A TW 94138786A TW I380829 B TWI380829 B TW I380829B
Authority
TW
Taiwan
Prior art keywords
solid dispersion
plenst
preparing
water
polymer
Prior art date
Application number
TW094138786A
Other languages
English (en)
Chinese (zh)
Other versions
TW200621307A (en
Inventor
Joon-Gyo Oh
Yong-Ho Oh
Ho-Chul Shin
Ji-Sun Jung
Key-An Um
Dong-Sun Min
Nam-Kyu Lee
Ju-Young Lee
Guang-Jin Im
Tae-Kon Kim
Jeong-Tae Kim
Woo-Jae Jang
Dong-Chul Shin
Woong-Sik Kim
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36319405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI380829(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of TW200621307A publication Critical patent/TW200621307A/zh
Application granted granted Critical
Publication of TWI380829B publication Critical patent/TWI380829B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW094138786A 2004-11-04 2005-11-04 具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法 TWI380829B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040089455A KR101086254B1 (ko) 2004-11-04 2004-11-04 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법

Publications (2)

Publication Number Publication Date
TW200621307A TW200621307A (en) 2006-07-01
TWI380829B true TWI380829B (zh) 2013-01-01

Family

ID=36319405

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094138786A TWI380829B (zh) 2004-11-04 2005-11-04 具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法

Country Status (6)

Country Link
JP (1) JP5232472B2 (enExample)
KR (1) KR101086254B1 (enExample)
AR (1) AR051758A1 (enExample)
MX (1) MX2007005427A (enExample)
TW (1) TWI380829B (enExample)
WO (1) WO2006049433A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101233235B1 (ko) * 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
EP2187968A4 (en) * 2007-08-21 2013-02-20 Univ Texas THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
EP2140861A1 (en) * 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
KR101381881B1 (ko) * 2012-03-12 2014-04-04 충남대학교산학협력단 용해도 및 용출율이 개선된 프란루카스트 나노 고체 분산체의 제조방법
KR101446129B1 (ko) * 2012-10-10 2014-10-06 조선대학교산학협력단 프란루카스트-함유 고형 제제의 제조방법
KR102191562B1 (ko) * 2012-11-07 2020-12-15 에스케이바이오팜 주식회사 난용성 약물의 고체분산체 및 이의 제조방법
KR102363727B1 (ko) 2015-06-01 2022-02-16 삼아제약 주식회사 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
WO2020012498A1 (en) 2018-07-13 2020-01-16 Council Of Scientific & Industrial Research Solid dispersion comprising an anticancer compound with improved solubility and efficacy
KR20240164596A (ko) 2023-05-09 2024-11-20 삼아제약 주식회사 복약편의성이 증진된 프란루카스트 함유 약제학적 조성물
KR102840220B1 (ko) 2023-07-18 2025-07-31 삼아제약 주식회사 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물
KR20250052834A (ko) 2023-10-12 2025-04-21 주식회사 다산제약 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834314A1 (en) * 1995-06-12 1998-04-08 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
WO2001089574A1 (en) * 2000-05-20 2001-11-29 Sang Deuk Lee Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
US20030215496A1 (en) * 1999-11-23 2003-11-20 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5858509A (en) * 1996-11-15 1999-01-12 Digital Equipment Corporation Attenuating vibrations in a mounting shelf for multiple disk drives
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834314A1 (en) * 1995-06-12 1998-04-08 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
US20030215496A1 (en) * 1999-11-23 2003-11-20 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001089574A1 (en) * 2000-05-20 2001-11-29 Sang Deuk Lee Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof

Also Published As

Publication number Publication date
MX2007005427A (es) 2012-10-02
KR101086254B1 (ko) 2011-11-24
TW200621307A (en) 2006-07-01
WO2006049433A1 (en) 2006-05-11
JP2008519067A (ja) 2008-06-05
AR051758A1 (es) 2007-02-07
KR20060040211A (ko) 2006-05-10
JP5232472B2 (ja) 2013-07-10

Similar Documents

Publication Publication Date Title
TWI389691B (zh) 可口服且具有活性成分快速釋出之固態醫藥劑型
EP2886109B1 (en) Medicament-containing hollow particle
WO2000024423A1 (en) Sustained-release particles
TWI380829B (zh) 具有改良的生物可利用率之普侖斯特（ｐｒａｎｌｕｋａｓｔ）固態分散物組成物及製備該固態分散物之方法
JP3967924B2 (ja) 溶出性の改善されたプランルカスト固体分散系及びその製造方法
JP7767651B2 (ja) Ｇｌｐ１医薬組成物
WO2011160541A1 (zh) 托伐普坦固体分散体及其制备方法
JP4856843B2 (ja) 新規フェノフィブラート錠剤
US20250325525A1 (en) Glp1 tablet compositions
KR100908418B1 (ko) 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
CN106619520A (zh) 一种右兰索拉唑钠的干混悬剂及其制备方法
CA2253769C (en) Pharmaceutical compositions comprising fenofibrate
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
JP5297194B2 (ja) 初期溶解率が改善されたプランルカスト固体分散体の薬剤学的組成物およびその製造方法
CN101227894A (zh) 口腔速崩片
WO2001085135A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ITRACONAZOLE WITH GASTRIC pH-INDEPENDENTLY IMPROVED SOLUBILITY AND PREPARATION METHOD THEREOF
JP3547009B1 (ja) ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の新規結晶、その製造方法およびその結晶を有効成分とする医薬
KR100981751B1 (ko) 프란루카스트를 함유하는 과립 및 그의 제조방법
JP2813792B2 (ja) マレイン酸イルソグラジン経口投与用製剤およびその製造法
CN106727381A (zh) 一种右兰索拉唑钠的口崩片及其制备方法
HK40049256A (en) Medicament-containing hollow particle
JP2004210766A (ja) ５−［（１ｚ，２ｅ）−２−メチル−３−フェニル−２−プロペニリデン］−４−オキソ−２−チオキソ−３−チアゾリジン酢酸の新規結晶の製造方法
HK1034906A1 (en) Method and composition of an oral preparation of itraconazole
HK1034906B (en) Method and composition of an oral preparation of itraconazole
HK1127284B (en) Solid orally administerable pharmaceutical dosage forms with rapid active principle release

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees